BioCryst Pharmaceuticals | BCRX - Umsatzkosten





Umsatzkosten Veränderung Datum
Alnylam Pharmaceuticals USD 267.72M 67.57M 2025-12
BioCryst Pharmaceuticals USD 9.52M 7.34M 2025-12
Chugai Pharma JPY 87.56B 12.68B 2025-12
Daiichi Sankyo JPY 118.28B 37.7B 2025-12
Gilead Sciences USD 1.62B 50M 2025-12
GlaxoSmithKline GBP 2.61B 377M 2025-12
Glaxosmithkline GBP 3.47B 461.37M 2025-12
Incyte USD 121.18M 22.18M 2025-12
Ionis Pharmaceuticals USD 8M 5.66M 2025-12
Karyopharm Therapeutics USD 37.43M 2.41M 2024-09
Neurocrine Biosciences USD 17.6M 246.4M 2025-12
Novavax USD 22.1M 608K 2025-12
PTC Therapeutics USD 16.3M 7.02M 2025-12
Regeneron Pharmaceuticals USD 584.6M 63M 2025-12
Roche Holding CHF 8.48B 4.61B 2025-12
Sarepta Therapeutics USD 399.38M 247.93M 2025-12
Ultragenyx Pharmaceutical USD 29M 1.01M 2025-12
Vertex Pharmaceuticals USD 466M 51.2M 2025-12